ERBB2 and neoplasm: Indeed, it has been demonstrated that gain-of-function mutations in oncogenes such as HER2 or EGFR and loss-of-function mutations in tumor-suppressor genes such as VHL or PTEN induce HIF-1 activity [28], [32], [33].